−/− mice showed significantly more severe chronic EAE there was a significant decrease in PD-L1-expressing mDC in the spleens and no differences in Foxp3 Treg. Furthermore, add back of mDC with increased PD-L1 expression to CCR6 −/− mice reduced the severe chronic EAE disease phase to that of wild type controls. The results suggest a role for CCR6-expressing PDL1 + mDC in regulating EAE progression.
Introduction

Experimental autoimmune encephalomyelitis (EAE) is a CD4
+ T cell-mediated demyelinating disease of the CNS that serves as a model for MS (Hohlfeld et al., 2000) . The pathogenic mechanisms of disease development include antigen-specific T cell activation and Th1 differentiation (Krakowski and Owens, 1997) followed by T cell (Hickey et al., 1991) and macrophage migration into CNS (Cross et al., 1990; Hickey, 1991) . More recently a role for IL-17 producing T cells (Th17) in disease pathogenesis has been demonstrated (Bettelli et al., 2006) . EAE can be induced in mice by immunization with whole myelin proteins or peptide emulsified in CFA (Tuohy et al., 1992) or by adoptive transfer of autoreactive T cells to normal recipient mice (Kuchroo et al., 1992; Whitham et al., 1991) . Macrophages activated by the effector T cell response appear to be the end stage disease effector cells inducing damage in the CNS (Brosnan et al., 1981; Dogan et al., 2008; Huitinga et al., 1990) . Chemokines are leukocyte chemoattractants that play a crucial role during pathogenesis of tissue-specific inflammatory diseases by directing leukocyte recruitment and/or accumulation at sites of inflammation (Murphy et al., 2000; Zlotnik and Yoshie, 2000) . Chemokines and their receptors have been implicated as functional mediators of immunopathology in EAE (Karpus et al., 2003; Karpus and Ransohoff, 1998) . CCL20 (MIP-3α) is a CC chemokine that has only one known receptor, CCR6 (Baba et al., 1997; Varona et al., 1998) , which is expressed on a variety of cell types including lymphocytes (Liao et al., 1999; Schutyser et al., 2003) , dendritic cells (DC) (Greaves et al., 1997) and Langerhans cells (LC) (Dieu-Nosjean et al., 2000) . CCL20 has been shown to be expressed by astrocytes in the CNS after EAE induction (Ambrosini et al., 2003) and in the periphery after immunization with spinal cord homogenate (Kohler et al., 2003) . Anti-CCL20 antibody treatments reduced clinical disease severity but failed to prevent the induction of disease (Kohler et al., 2003) . Similarly, CCR6
−/− mice also have been shown to have a delay in the development of acute EAE (Liston et al., 2009) . These studies suggested a role for CCL20 and its receptor in priming peripheral immune responses. More recently it was shown that EAE-inducing Th17 cells expressed CCR6 (Yamazaki et al., 2008) . We sought to address the mechanism by which the CCL20 receptor, CCR6, regulated chronic EAE pathogenesis. In the present report, we demonstrate that CCR6 plays a role in the control of chronic EAE by modulating the migration of regulatory DC. 
Materials and methods
Animals
